Second Asian jackpot for Cara's kappa agonist
This article was originally published in Scrip
Executive Summary
The US venture Cara Therapeutics has struck a second licensing deal for its lead analgesic candidate CR845, this time awarding exclusive development, manufacturing and commercialization rights in Japan to Maruishi Pharmaceutical.